國立高雄大學圖資館 |

Language: English

Back

Retinal degenerative diseasesmechani...

Ash, John D.

Retinal degenerative diseasesmechanisms and experimental therapy /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Retinal degenerative diseasesedited by John D. Ash ... [et al.].
Reminder of title:	mechanisms and experimental therapy /
other author:	Ash, John D.
Published:	Cham :Springer International Publishing :2018.
Description:	xlii, 669 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Retinal degeneration.
Online resource:	http://dx.doi.org/10.1007/978-3-319-75402-4
ISBN:	9783319754024$q(electronic bk.)

Retinal degenerative diseasesmechanisms and experimental therapy /
Retinal degenerative diseasesmechanisms and experimental therapy /[electronic resource] :edited by John D. Ash ... [et al.]. - Cham :Springer International Publishing :2018. - xlii, 669 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,10740065-2598 ;. - Advances in experimental medicine and biology ;946..

The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

ISBN: 9783319754024$q(electronic bk.)

Standard No.: 10.1007/978-3-319-75402-4doiSubjects--Topical Terms:

522814
Retinal degeneration.

LC Class. No.: RE661.D3 / R485 2018

Dewey Class. No.: 617.735

Retinal degenerative diseasesmechanisms and experimental therapy /
LDR:03463nmm a2200313 a 4500 001 537607
003 DE-He213
005 20181105142419.0
006 m d
007 cr nn 008maaau
008 190116s2018 gw s 0 eng d
020 $a 9783319754024$q(electronic bk.)
020 $a 9783319754017$q(paper)
024 7 $a 10.1007/978-3-319-75402-4 $2 doi
035 $a 978-3-319-75402-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RE661.D3 $b R485 2018
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
082 0 4 $a 617.735 $2 23
090 $a RE661.D3 $b R438 2018
245 0 0 $a Retinal degenerative diseases $h [electronic resource] : $b mechanisms and experimental therapy / $c edited by John D. Ash ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xlii, 669 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v 1074
520 $a The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.
650 0 $a Retinal degeneration. $3 522814
650 0 $a Medicine. $3 193819
650 0 $a Neurosciences. $3 211508
650 0 $a Ophthalmology. $3 274149
650 1 4 $a Biomedicine. $3 273648
700 1 $a Ash, John D. $3 679372
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-75402-4
950 $a Biomedical and Life Sciences (Springer-11642)